Antares Pharma to Host Third Quarter 2009 Earnings Call

EWING, N.J.--(Business Wire)--
Antares Pharma, Inc. (Amex: AIS) today announced that it will release its third
quarter 2009 financial results after the market closes on Monday, November 9,
2009, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to
discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive
Officer, and Robert F. Apple, Executive Vice President and Chief Financial
Officer, will host the call.

Interested parties may participate in the conference call by dialing
1-800-762-8908 (US), or 480-629-9774 (International), 5-10 minutes prior to the
start of the call. A replay of the conference call will be available
approximately 2 hours after the call's conclusion through 12:00 PM Eastern Time
on November 23, 2009 by dialing 800-406-7325 (US), or 303-590-3030
(International), and entering reservation #4181042. An audio web cast and
archive of the conference call will also be available under the investor
relations section of the Antares website at www.antarespharma.com.

About Antares Pharma (www.antarespharma.com)

Antares Pharma focuses on self-injection delivery technologies and topical
gel-based pharmaceutical products. The company`s subcutaneous injection
technology platforms include VibexTM disposable pressure-assisted auto
injectors, ValeoTM/Vision reusable needle-free injectors, and disposable
multi-use pen injectors. In the injector area, Antares Pharma has a
multi-product deal with Teva Pharmaceuticals Industries, Ltd that includes
Tev-Tropin human growth hormone and a partnership with Ferring Pharmaceuticals.
In the gel-based area, the company`s lead product candidate, Anturol, an
oxybutynin ATD gel for the treatment of OAB (overactive bladder), is currently
under evaluation in a pivotal Phase 3 trial. Antares also has a partnership with
BioSante that includes LibiGel (transdermal testosterone gel) in Phase III
clinical development for the treatment of female sexual dysfunction (FSD), and
Elestrin (estradiol gel) indicated for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause, and currently marketed in the U.S.
Antares Pharma has corporate headquarters in Ewing, New Jersey, with
subsidiaries performing research, development, manufacturing and product
commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Antares Pharma
Robert Apple
Chief Financial Officer
609-359-3020
or
Westwicke Partners, LLC
John Woolford
443-213-0506
john.woolford@westwicke.com

Copyright Business Wire 2009